Decreased memory B cells, CD8+T cells and Tregs, and increased M0 and M2 macrophages in a fraction of metastatic tumors with a high PD-L2/ICOS ratio, may suggest future prospective therapeutic trials in this patient subpopulation. This evidence concerns the gene PDCD1LG2 and metastatic neoplasm.